Head or Neck Cancer Clinical Trial
Official title:
Phase II Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies
This phase II study will test the response rate of combined oxaliplatin and capecitabine treatment when administered at a given dose and schedule, in patients with Head and Neck cancer for which there is no curative treatment.
The optimal dose and schedule for the combined treatment with oxaliplatin and capecitabine
have not been defined. The aim of this Phase II study is to determine the response rate of
combined oxaliplatin and capecitabine treatment at a given dose and schedule in patients with
Head and Neck cancer for which there is no curative treatment.
The study also aims to determine the qualitative and quantitative toxicity and reversibility
of toxicity of the above combination and to evaluate any changes in performance status,
quality of life, overall survival and progression-free survival.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02474368 -
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
|
Phase 1 | |
| Completed |
NCT02374255 -
Improving Goals of Care Discussion in Advanced Cancer Patients
|
N/A |